A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

Science Translational Medicine

Volumn 7, Issue 270, 2015, Pages

  Andrews, Chasity D ^a   Yueh, Yun Lan ^b   Spreen, William R ^b   St Bernard, Leslie ^a   Boente Carrera, Mar ^a   Rodriguez, Kristina ^a   Gettie, Agegnehu ^a   Russell Lodrigue, Kasi ^c   Blanchard, James ^c   Ford, Susan ^b   Mohri, Hiroshi ^a   Cheng Mayer, Cecilia ^a   Hong, Zhi ^b   Ho, David D ^a   Markowitz, Martin ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOTEGRAVIR; INTEGRASE INHIBITOR; LONG ACTING DRUG; MEDROXYPROGESTERONE ACETATE; ANTIRETROVIRUS AGENT; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NONHUMAN; PRE-EXPOSURE PROPHYLAXIS; RECTUM; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERINE CERVIX; VAGINA; VIREMIA; VIRUS TRANSMISSION; ANIMAL; CHEMISTRY; DRUG EFFECTS; INTRAVAGINAL DRUG ADMINISTRATION; MACACA; MOLECULAR GENETICS; MUTATION; SIMIAN IMMUNODEFICIENCY VIRUS; STATISTICAL MODEL; VIROLOGY; VIRUS GENOME; VIRUS LOAD;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-RETROVIRAL AGENTS; FEMALE; GENOME, VIRAL; INTEGRASE INHIBITORS; LIKELIHOOD FUNCTIONS; MACACA; MEDROXYPROGESTERONE ACETATE; MOLECULAR SEQUENCE DATA; MUTATION; PYRIDONES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA; VIRAL LOAD;

EID: 84921047798     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3010298     Document Type: Article

References (59)

1. R. M. Grant, J. R. Lama, P. L. Anderson, V. McMahan, A. Y. Liu, L. Vargas, P. Goicochea, M. Casapía, J. V. Guanira-Carranza, M. E. Ramirez-Cardich, O. Montoya-Herrera, T. Fernaádez, V. G. Veloso, S. P. Buchbinder, S. Chariyalertsak, M. Schechter, L. G. Bekker, K. H. Mayer, E. G. Kallás, K. R. Amico, K. Mulligan, L. R. Bushman, R. J. Hance, C. Ganoza, P. Defechereux, B. Postle, F. Wang, J. J. McConnell, J. H. Zheng, J. Lee, J. F. Rooney, H. S. Jaffe, A. I. Martinez, D. N. Burns, D. V. Glidden; iPrEx Study Team, Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587-2599 (2010).
2. J. M. Baeten, D. Donnell, P. Ndase, N. R. Mugo, J. D. Campbell, J. Wangisi, J. W. Tappero, E. A. Bukusi, C. R. Cohen, E. Katabira, A. Ronald, E. Tumwesigye, E. Were, K. H. Fife, J. Kiarie, C. Farquhar, G. John-Stewart, A. Kakia, J. Odoyo, A. Mucunguzi, E. Nakku-Joloba, R. Twesigye, K. Ngure, C. Apaka, H. Tamooh, F. Gabona, A. Mujugira, D. Panteleeff, K. K. Thomas, L. Kidoguchi, M. Krows, J. Revall, S. Morrison, H. Haugen, M. Emmanuel-Ogier, L. Ondrejcek, R. W. Coombs, L. Frenkel, C. Hendrix, N. N. Bumpus, D. Bangsberg, J. E. Haberer, W. S. Stevens, J. R. Lingappa, C. Celum; Partners PrEP Study Team, Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399-410 (2012).
3. M. C. Thigpen, P. M. Kebaabetswe, L. A. Paxton, D. K. Smith, C. E. Rose, T. M. Segolodi, F. L. Henderson, S. R. Pathak, F. A. Soud, K. L. Chillag, R. Mutanhaurwa, L. I. Chirwa, M. Kasonde, D. Abebe, E. Buliva, R. J. Gvetadze, S. Johnson, T. Sukalac, V. T. Thomas, C. Hart, J. A. Johnson, C. K. Malotte, C. W. Hendrix, J. T. Brooks; TDF2 Study Group, Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367, 423-434 (2012).
4. K. Choopanya, M. Martin, P. Suntharasamai, U. Sangkum, P. A. Mock, M. Leethochawalit, S. Chiamwongpaet, P. Kitisin, P. Natrujirote, S. Kittimunkong, R. Chuachoowong, R. J. Gvetadze, J. M. McNicholl, L. A. Paxton, M. E. Curlin, C. W. Hendrix, S. Vanichseni; Bangkok Tenofovir Study Group, Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381, 2083-2090 (2013).
5. Q. Abdool Karim, S. S. Abdool Karim, J. A. Frohlich, A. C. Grobler, C. Baxter, L. E. Mansoor, A. B. Kharsany, S. Sibeko, K. P. Mlisana, Z. Omar, T. N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, D. Taylor; CAPRISA 004 Trial Group, Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010).
6. L. Van Damme, A. Corneli, K. Ahmed, K. Agot, J. Lombaard, S. Kapiga, M. Malahleha, F. Owino, R. Manongi, J. Onyango, L. Temu, M. C. Monedi, P. Mak'Oketch, M. Makanda, I. Reblin, S. E. Makatu, L. Saylor, H. Kiernan, S. Kirkendale, C. Wong, R. Grant, A. Kashuba, K. Nanda, J. Mandala, K. Fransen, J. Deese, T. Crucitti, T. D. Mastro, D. Taylor; FEM-PrEP Study Group, Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367, 411-422 (2012).
7. J. Marrazzo, G. Ramjee, G. Nair, T. Palanee, B. Mkhize, C. Nakabiito, M. Taljaard, J. Piper, K. Gomez Feliciano, M. Chirenje, VOICE Study Team, Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013.
8. W. R. Spreen, D. A. Margolis, J. C. Pottage Jr., Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr. Opin. HIV AIDS 8, 565-571 (2013).
9. W. Spreen, P. Williams, D. Margolis, S. Ford, H. Crauwels, Y. Lou, E. Gould, M. Stevens, S. Piscitelli, paper presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, 2013.
10. W. Spreen, S. Min, S. L. Ford, S. Chen, Y. Lou, M. Bomar, M. St Clair, S. Piscitelli, T. Fujiwara, Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin. Trials 14, 192-203 (2013).
11. C. D. Andrews, W. R. Spreen, H. Mohri, L. Moss, S. Ford, K. Russell-Lodrigue, R. P. Bohm, C. Cheng-Mayer, Z. Hong, M. Markowitz, D. D. Ho, Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 343, 1151-1154 (2014).
12. S. Subbarao, R. A. Otten, A. Ramos, C. Kim, E. Jackson, M. Monsour, D. R. Adams, S. Bashirian, J. Johnson, V. Soriano, A. Rendon, M. G. Hudgens, S. Butera, R. Janssen, L. Paxton, A. E. Greenberg, T. M. Folks, Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J. Infect. Dis. 194, 904-911 (2006).
13. S. Subbarao, A. Ramos, C. Kim, D. Adams, M. Monsour, S. Butera, T. Folks, R. A. Otten, Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention. J. Med. Primatol. 36, 238-243 (2007).
14. J. G. García-Lerma, R. A. Otten, S. H. Qari, E. Jackson, M. E. Cong, S. Masciotra, W. Luo, C. Kim, D. R. Adams, M. Monsour, J. Lipscomb, J. A. Johnson, D. Delinsky, R. F. Schinazi, R. Janssen, T. M. Folks, W. Heneine, Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLOS Med. 5, e28 (2008).
15. A. J. Hessell, P. Poignard, M. Hunter, L. Hangartner, D. M. Tehrani, W. K. Bleeker, P. W. Parren, P. A. Marx, D. R. Burton, Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15, 951-954 (2009).
16. UNAIDS, UNAIDS Report on the Global AIDS Epidemic (2013).
17. Z. Ma, F. X. Lü, M. Torten, C. J. Miller, The number and distribution of immune cells in the cervicovaginal mucosa remain constant throughout the menstrual cycle of rhesus macaques. Clin. Immunol. 100, 240-249 (2001).
18. D. L. Sodora, A. Gettie, C. J. Miller, P. A. Marx, Vaginal transmission of SIV: Assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res. Hum. Retroviruses 14 (Suppl. 1), S119-S123 (1998).
19. P. F. Parakkal, A. T. Gregoire, Differentiation of vaginal epithelium in the normal and hormone-treated rhesus monkey. Biol. Reprod. 6, 117-130 (1972).
20. P. A. Marx, A. I. Spira, A. Gettie, P. J. Dailey, R. S. Veazey, A. A. Lackner, C. J. Mahoney, C. J. Miller, L. E. Claypool, D. D. Ho, N. J. Alexander, S.I.V., Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 2, 1084-1089 (1996).
21. R. S. Veazey, R. J. Shattock, M. Pope, J. C. Kirijan, J. Jones, Q. Hu, T. Ketas, P. A. Marx, P. J. Klasse, D. R. Burton, J. P. Moore, Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9, 343-346 (2003).
22. R. S. Veazey, P. J. Klasse, T. J. Ketas, J. D. Reeves, M. Piatak Jr., K. Kunstman, S. E. Kuhmann, P. A. Marx, J. D. Lifson, J. Dufour, M. Mefford, I. Pandrea, S. M. Wolinsky, R. W. Doms, J. A. DeMartino, S. J. Siciliano, K. Lyons, M. S. Springer, J. P. Moore, Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J. Exp. Med. 198, 1551-1562 (2003).
23. R. S. Veazey, M. S. Springer, P. A. Marx, J. Dufour, P. J. Klasse, J. P. Moore, Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat. Med. 11, 1293-1294 (2005).
24. D. R. Burton, A. J. Hessell, B. F. Keele, P. J. Klasse, T. A. Ketas, B. Moldt, D. C. Dunlop, P. Poignard, L. A. Doyle, L. Cavacini, R. S. Veazey, J. P. Moore, Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. U.S.A. 108, 11181-11186 (2011).
25. D. H. Barouch, P. J. Klasse, J. Dufour, R. S. Veazey, J. P. Moore, Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc. Natl. Acad. Sci. U.S.A. 109, 8694-8698 (2012).
26. K. Klein, R. S. Veazey, R. Warrier, P. Hraber, L. A. Doyle-Meyers, V. Buffa, H. X. Liao, B. F. Haynes, G. M. Shaw, R. J. Shattock, Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. J. Virol. 87, 11604-11616 (2013).
27. M. M. Lederman, R. S. Veazey, R. Offord, D. E. Mosier, J. Dufour, M. Mefford, M. Piatak Jr., J. D. Lifson, J. R. Salkowitz, B. Rodriguez, A. Blauvelt, O. Hartley, Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306, 485-487 (2004).
28. R. S. Veazey, P. J. Klasse, S. M. Schader, Q. Hu, T. J. Ketas, M. Lu, P. A. Marx, J. Dufour, R. J. Colonno, R. J. Shattock, M. S. Springer, J. P. Moore, Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438, 99-102 (2005).
29. R. S. Veazey, T. A. Ketas, P. J. Klasse, D. K. Davison, M. Singletary, L. C. Green, M. L. Greenberg, J. P. Moore, Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proc. Natl. Acad. Sci. U.S.A. 105, 10531-10536 (2008).
30. R. S. Veazey, B. Ling, L. C. Green, E. P. Ribka, J. D. Lifson, M. Piatak Jr., M. M. Lederman, D. Mosier, R. Offord, O. Hartley, Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J. Infect. Dis. 199, 1525-1527 (2009).
31. R. S. Veazey, T. J. Ketas, J. Dufour, T. Moroney-Rasmussen, L. C. Green, P. J. Klasse, J. P. Moore, Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J. Infect. Dis. 202, 739-744 (2010).
32. R. A. Otten, D. R. Adams, C. N. Kim, E. Jackson, J. K. Pullium, K. Lee, L. A. Grohskopf, M. Monsour, S. Butera, T. M. Folks, Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: Strategy to study HIV preclinical interventions in nonhuman primates. J. Infect. Dis. 191, 164-173 (2005).
33. C. N. Kim, D. R. Adams, S. Bashirian, S. Butera, T. M. Folks, R. A. Otten, Repetitive exposures with simian/human immunodeficiency viruses: Strategy to study HIV pre-clinical interventions in non-human primates. J. Med. Primatol. 35, 210-216 (2006).
34. J. M. McNicholl, T. C. Henning, S. A. Vishwanathan, E. N. Kersh, Non-human primate models of hormonal contraception and HIV. Am. J. Reprod. Immunol. 71, 513-522 (2014).
35. J. Radzio, W. Spreen, Y. L. Yueh, J. Mitchell, L. Jenkins, J. G. García-Lerma, W. Heneine, The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci. Transl. Med. 7, 270ra5 (2015).
36. J. B. Dumond, R. F. Yeh, K. B. Patterson, A. H. Corbett, B. H. Jung, N. L. Rezk, A. S. Bridges, P. W. Stewart, M. S. Cohen, A. D. Kashuba, Antiretroviral drug exposure in the female genital tract: Implications for oral pre- and post-exposure prophylaxis. AIDS 21, 1899-1907 (2007).
37. M. R. Nicol, A. D. Kashuba, Pharmacologic opportunities for HIV prevention. Clin. Pharmacol. Ther. 88, 598-609 (2010).
38. K. C. Brown, K. B. Patterson, S. A. Malone, N. J. Shaheen, H. M. Prince, J. B. Dumond, M. B. Spacek, P. E. Heidt, M. S. Cohen, A. D. Kashuba, Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J. Infect. Dis. 203, 1484-1490 (2011).
39. J. B. Dumond, K. B. Patterson, A. L. Pecha, R. E. Werner, E. Andrews, B. Damle, R. Tressler, J. Worsley, A. D. Kashuba, Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J. Acquir. Immune Defic. Syndr. 51, 546-553 (2009).
40. B. F. Keele, E. E. Giorgi, J. F. Salazar-Gonzalez, J. M. Decker, K. T. Pham, M. G. Salazar, C. Sun, T. Grayson, S. Wang, H. Li, X. Wei, C. Jiang, J. L. Kirchherr, F. Gao, J. A. Anderson, L. H. Ping, R. Swanstrom, G. D. Tomaras, W. A. Blattner, P. A. Goepfert, J. M. Kilby, M. S. Saag, E. L. Delwart, M. P. Busch, M. S. Cohen, D. C. Montefiori, B. F. Haynes, B. Gaschen, G. S. Athreya, H. Y. Lee, N. Wood, C. Seoighe, A. S. Perelson, T. Bhattacharya, B. T. Korber, B. H. Hahn, G. M. Shaw, Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U.S.A. 105, 7552-7557 (2008).
41. A. M. Tsibris, U. Pal, A. L. Schure, R. S. Veazey, K. J. Kunstman, T. J. Henrich, P. J. Klasse, S. M. Wolinsky, D. R. Kuritzkes, J. P. Moore, SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PLOS One 6, e28047 (2011).
42. J. Liu, B. F. Keele, H. Li, S. Keating, P. J. Norris, A. Carville, K. G. Mansfield, G. D. Tomaras, B. F. Haynes, D. Kolodkin-Gal, N. L. Letvin, B. H. Hahn, G. M. Shaw, D. H. Barouch, Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J. Virol. 84, 10406-10412 (2010).
43. M. Reese, S. Ford, G. Bowers, J. Humphreys, L. Webster, E. Gould, J. Polli, G. Generaux, M. Johnson, P. Clark, C. Watson, Y. Lou, S. Piscitelli, International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, DC, 2014.
44. H. Jeong, S. Choi, J. W. Song, H. Chen, J. H. Fischer, Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica 38, 62-75 (2008).
45. J. Radzio, K. Hanley, J. Mitchell, S. Ellis, F. Deyounks, L. T. Jenkins, D. Hanson, W. Heneine, J. G. García-Lerma, Physiologic doses of depot-medroxyprogesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques. AIDS 28, 1431-1439 (2014).
46. W. Spreen, S. L. Ford, S. Chen, D. Wilfret, D. Margolis, E. Gould, S. Piscitelli, GSK1265744 pharmacokinetics in plasma and tissue following single-dose long-acting (LA) injectable administration in healthy subjects. J. Acquir. Immune Defic. Syndr. 67, 481-486 (2014).
47. R. K. Malcolm, R. S. Veazey, L. Geer, D. Lowry, S. M. Fetherston, D. J. Murphy, P. Boyd, I. Major, R. J. Shattock, P. J. Klasse, L. A. Doyle, K. K. Rasmussen, L. Goldman, T. J. Ketas, J. P. Moore, Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob. Agents Chemother. 56, 2251-2258 (2012).
48. M. J. Wawer, R. H. Gray, N. K. Sewankambo, D. Serwadda, X. Li, O. Laeyendecker, N. Kiwanuka, G. Kigozi, M. Kiddugavu, T. Lutalo, F. Nalugoda, F. Wabwire-Mangen, M. P. Meehan, T. C. Quinn, Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J. Infect. Dis. 191, 1403-1409 (2005).
49. C. D. Pilcher, H. C. Tien, J. J. Eron Jr., P. L. Vernazza, S. Y. Leu, P. W. Stewart, L. E. Goh, M. S. Cohen; Quest Study; Duke-UNC-Emory Acute HIV Consortium, Brief but efficient: Acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189, 1785-1792 (2004).
50. Z. Hel, E. Stringer, J. Mestecky, Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr. Rev. 31, 79-97 (2010).
51. T. C. Quinn, J. Overbaugh, HIV/AIDS in women: An expanding epidemic. Science 308, 1582-1583 (2005).
52. S. A. Vishwanathan, P. C. Guenthner, C. Y. Lin, C. Dobard, S. Sharma, D. R. Adams, R. A. Otten, W. Heneine, R. M. Hendry, J. M. McNicholl, E. N. Kersh, High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J. Acquir. Immune Defic. Syndr. 57, 261-264 (2011).
53. M. Stone, B. F. Keele, Z. M. Ma, E. Bailes, J. Dutra, B. H. Hahn, G. M. Shaw, C. J. Miller, A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J. Virol. 84, 7083-7095 (2010).
54. B. Winner, J. F. Peipert, Q. Zhao, C. Buckel, T. Madden, J. E. Allsworth, G. M. Secura, Effectiveness of long-acting reversible contraception. N. Engl. J. Med. 366, 1998-2007 (2012).
55. G. Rossi, S. Frediani, R. Rossi, A. Rossi, Long-acting antipsychotic drugs for the treatment of schizophrenia: Use in daily practice from naturalistic observations. BMC Psychiatry 12, 122 (2012).
56. V. A. Giagulli, V. Triggiani, G. Corona, D. Carbone, B. Licchelli, E. Tafaro, F. Resta, C. Sabbà, M. Maggi, E. Guastamacchia, Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: Focus on new formulations. Curr. Pharm. Des. 17, 1500-1511 (2011).
57. J. M. Harouse, A. Gettie, T. Eshetu, R. C. Tan, R. Bohm, J. Blanchard, G. Baskin, C. Cheng-Mayer, Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J. Virol. 75, 1990-1995 (2001).
58. J. M. Harouse, A. Gettie, R. C. Tan, J. Blanchard, C. Cheng-Mayer, Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284, 816-819 (1999).
59. L. J. Reed, H. Muench, A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497 (1938).